Sunday 18 October 2026 Export FHTX’s income statement to Excel — free account

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.

1.85 0.04 −2.12%

Follow FHTX

Alert me

Market cap: $112.2M
P/E: 0.0×
Fwd P/E: −3.7×
Dividend yield: —
F-score: 2/9
Altman Z: −4.46
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 55.67%

Capital & Financial Ratios $m

Market Cap 112.24

Revenue 36.74

Net Income (64.58)

Free Cash Flow (84.31)

Net Debt (167.58)

Current Ratio 3.36

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.66)

P/S ratio 3.56

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 23.04%

Next Y EPS Growth 9.71%

Next Y revenue growth (7.11%)

Next 5Y EPS Growth 14.13%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.30%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	234	244	160	168
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	240	250	163	170

	2023	2024	2025	Q'26
Payables	6	4	4	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	58	67	60	51

Compound Annual Growth %

	10y	5y	3y
Sales	—	135.14%	17.14%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	16	—	—	—
’25	6	8	8	9	31
’24	5	7	8	3	23
’23	5	6	17	6	34
’22	4	4	7	4	19
’21	0	0	0	1	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(25)	(18)	—	—	—
’25	(24)	(21)	(19)	(22)	(86)
’24	(29)	(26)	(21)	(25)	(100)
’23	(31)	(32)	(27)	(28)	(118)
’22	272	(29)	(20)	(29)	194
’21	(23)	(18)	(21)	12	(50)
’20	(11)	(13)	3	(11)	(31)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(25)	(18)	—	—	—
’25	(24)	(21)	(19)	(22)	(86)
’24	(29)	(26)	(21)	(25)	(101)
’23	(32)	(33)	(27)	(28)	(119)
’22	271	(29)	(20)	(29)	192
’21	(25)	(20)	(21)	12	(54)
’20	(12)	(15)	(3)	(18)	(47)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.29)	(0.10)	—	—	—
’25	(0.30)	(0.28)	(0.25)	(0.34)	(1.18)
’24	(0.59)	(0.45)	(0.31)	(0.30)	(1.58)
’23	(0.73)	(0.70)	(0.34)	(0.57)	(2.34)
’22	(0.65)	(0.66)	(0.62)	(0.69)	(2.62)
’21	(0.62)	(0.63)	(0.71)	(0.77)	(2.73)
’20	(2.71)	(2.90)	(3.12)	2.50	(6.23)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	14.03	8.01	5.32	2.84	2.70	2.95	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	28.27	25.10	24.34	9.97	10.25	6.79
People
People	Employees	—	—	—	85	95	119	161	116	112	106
	Revenue/emp, $m	—	—	—	0.00	0.00	0.01	0.12	0.29	0.20	0.29
Income, $m
Income, $m	Revenue	—	—	—	—	0	1	19	34	23	31
	Gross margin, %	—	—	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(26)	(51)	(69)	(101)	(109)	(94)	(87)	(74)
	EBT margin, %	—	—	0.00	0.00	(16,000.00)	(7,681.58)	(566.27)	(275.80)	(383.24)	(240.33)
	Net income	—	0	(26)	(51)	(69)	(101)	(109)	(98)	(87)	(74)
	Depreciation	—	—	0	1	1	3	2	1	(1)	1
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.04	0.04	0.46	0.81	0.41	0.49
	Earnings	—	—	(0.72)	(12.20)	(6.23)	(2.73)	(2.62)	(2.34)	(1.58)	(1.18)
	Cash flow	—	—	(0.62)	(11.05)	(2.83)	(1.35)	4.66	(2.81)	(1.83)	(1.37)
	Capex	—	—	0.00	(0.23)	(1.44)	(0.09)	(0.03)	(0.03)	(0.02)	0.00
	Free cash flow	—	—	(0.62)	(11.28)	(4.27)	(1.44)	4.63	(2.84)	(1.85)	(1.37)
	Book value	—	—	(1.07)	(0.35)	13.23	2.61	0.00	(1.84)	(0.83)	(1.72)
	Shares, m	—	—	37	4	11	37	42	42	55	63
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	644.51	14.06	7.93	11.46	11.00
	P/B	—	—	—	—	1.53	8.78	2,413.79	0.00	0.00	0.00
	EV/Sales	—	—	—	—	0.00	542.63	(2.89)	1.66	1.56	6.47
	EV/FCF	—	—	—	—	(1.22)	(13.36)	(0.29)	(0.47)	(0.35)	(2.32)
Cash, $m
Cash, $m	Operating cash flow	—	—	(23)	(46)	(31)	(50)	194	(118)	(100)	(86)
	Capex	—	—	(2)	(1)	(16)	(3)	(1)	(1)	(1)	0
	Free cash flow	—	—	(23)	(47)	(47)	(54)	192	(119)	(101)	(86)
Balance, $m
Balance, $m	Working capital	—	—	37	4	172	411	296	182	183	103
	Total debt	—	—	78	11	20	51	46	—	—	—
	Net debt	—	—	38	(5)	(166)	(154)	(346)	(234)	(244)	(160)
	Shareholders’ equity	—	—	(39)	(1)	146	97	0	(77)	(46)	(108)
Returns, %
Returns, %	ROA	—	—	(122.33)	(156.35)	(49.51)	(26.13)	(23.55)	(28.50)	(30.40)	(30.82)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	41.38	80.33	(236.54)	(83.37)	(224.54)	255.39	141.17	96.45

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NERV Minerva Neurosciences, Inc	$115.6M	— (loss-making)	— (loss-making)	—	n/m	−553.48% (below 0%: shrinking)	0.00%	0.00%	Compare
ARMP Armata Pharmaceuticals, Inc.	$114.9M	— (loss-making)	— (loss-making)	+15.72% (above 0%: growing)	n/m	−17.98% (below 0%: shrinking)	100.00%	(410.84%)	Compare
ENGN enGene Therapeutics Inc	$114.6M	— (loss-making)	—	—	n/m	+28.07% (above 0%: growing)	—	0.00%	Compare
SEER Seer, Inc.	$113.0M	— (loss-making)	— (loss-making)	−23.43% (below 0%: shrinking)	n/m	+36.73% (above 0%: growing)	48.55%	(542.91%)	Compare
FHTX Foghorn Therapeutics Inc.	$112.2M	— (loss-making)	— (loss-making)	+112.68% (above 0%: growing)	n/m	+14.88% (above 0%: growing)	100.00%	(54.78%)
GNLX Genelux Corporation	$112.2M	— (loss-making)	— (loss-making)	—	n/m	−11.18% (below 0%: shrinking)	100.00%	0.00%	Compare
LENZ LENZ Therapeutics, Inc.	$112.2M	— (loss-making)	— (loss-making)	+9.72% (above 0%: growing)	n/m	−229.66% (below 0%: shrinking)	94.90%	(622.89%)	Compare
TNXP Tonix Pharmaceuticals Holding Corp.	$110.1M	— (loss-making)	— (loss-making)	+577.88% (above 0%: growing)	n/m	−178.84% (below 0%: shrinking)	94.81%	(314.05%)	Compare
VTVT vTv Therapeutics Inc.	$109.1M	— (loss-making)	— (loss-making)	+409,222.22% (above 0%: growing)	n/m	−124.59% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$112.6M	—	—	+15.72%	—	−71.28%	94.90%	(157.02%)

All 614 Biotechnology stocks →

Foghorn Therapeutics Inc. (FHTX) key facts

Strength: Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024.
Foghorn Therapeutics Inc. (FHTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, FHTX traded at $1.85, a market capitalization of $112.2 million.
Return on equity was 96.5% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −4.46 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.